⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6221240 | 0.63 | EGLN2 (0.31) | — | |
| SCHEMBL3682603 | 0.61 | — | — | |
| SCHEMBL665412 | 0.60 | SMN1; SMN2 (0.32) | — | |
| SCHEMBL4318445 | 0.59 | — | — | |
| SCHEMBL519284 | 0.58 | — | — | |
| SCHEMBL268655 | 0.56 | — | — | |
| SCHEMBL974506 | 0.55 | HDAC1 (0.33) | — | |
| SCHEMBL1031415 | 0.54 | SMN1; SMN2 (0.52) | — | |
| SCHEMBL5252362 | 0.54 | TGFBR1 (0.33) | — | |
| SCHEMBL15062613 | 0.48 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 124 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4160835-A | Antihypertensive compositions containing an arylsubstituted alanine and a phenyl hydrazinopropionic acid | MERCK & CO., INC. (US) | 1979-07-10 | — | — | US | claimed |
| US-20240238460-A1 | IMPROVED PROSTATE-SPECIFIC MEMBRANE ANTIGEN TARGETING RADIOPHARMACEUTICALS AND USES THEREOF | TELIX PHARMACEUTICALS INNOVATIONS PTY LTD (AU) | 2024-07-18 | — | — | US | disclosed |
| US-12030866-B2 | 2-pyrazole anilines and related analogs for inhibiting YAP/TAZ-TEAD | SPRINGWORKS THERAPEUTICS, INC. (US) | 2024-07-09 | — | — | US | disclosed |
| WO-2024115733-A1 | FUSED PYRROLYL-SULFONAMIDE COMPOUNDS | REWIND THERAPEUTICS NV (BE) | 2024-06-06 | — | — | WO | disclosed |
| EP-4347541-A2 | IMPROVED PROSTATE-SPECIFIC MEMBRANE ANTIGEN TARGETING RADIOPHARMACEUTICALS AND USES THEREOF | Telix Pharmaceuticals (Innovations) Pty Ltd (AU) | 2024-04-10 | — | — | EP | disclosed |
| EP-4347558-A1 | 3-PYRROLYLSULFONAMIDE COMPOUNDS AS GPR17 ANTAGONISTS | ReWind Therapeutics NV (BE) | 2024-04-10 | — | — | EP | disclosed |
| WO-2024059119-A2 | COMPOUNDS AND THEIR USE IN FILTERING ULTRAVIOLET AND/OR HIGH-ENERGY VISIBLE LIGHT | SOLIOME, INC. (US) | 2024-03-21 | — | — | WO | disclosed |
| US-20240059688-A1 | CONOLIDINE ANALOGUES AS SELECTIVE ACKR3 MODULATORS FOR THE TREATMENT OF CANCER | LUXEMBOURG INSTITUTE OF HEALTH (LIH) (LU) | 2024-02-22 | — | — | US | disclosed |
| WO-2024033479-A1 | (AZA)SPIROHEPTANE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | REMYND N.V. (BE) | 2024-02-15 | — | — | WO | disclosed |
| US-20240025856-A1 | 1,2,3,4-TETRAHYDROQUINOLINE DERIVATIVES AS INHIBITORS OF THE YAP/TAZ-TEAD ACTIVATION FOR TREATING CANCER | CISTIM LEUVEN VZW (BE) | 2024-01-25 | — | — | US | disclosed |
| WO-2013030216-A1 | NOVEL SOFT ROCK INHIBITORS | AMAKEM NV (BE) | 2013-03-07 | — | — | WO | disclosed |
| WO-2013030366-A1 | NOVEL SOFT ROCK INHIBITORS | AMAKEM NV (BE) | 2013-03-07 | — | — | WO | disclosed |
| WO-2013030367-A1 | BIPHENYLCARBOXAMIDES AS ROCK KINASE INHIBITORS | AMAKEM NV (BE) | 2013-03-07 | — | — | WO | disclosed |
| WO-2013021021-A1 | NOVEL SOFT PDE4 INHIBITORS | AMAKEM NV (BE) | 2013-02-14 | — | — | WO | disclosed |
| WO-2013004709-A1 | INDOLYLMALEIMIDES AS SOFT PAN-PKC INHIBITORS | AMAKEM NV (BE) | 2013-01-10 | — | — | WO | disclosed |
| EP-2542528-A1 | HETEROCYCLIC AMIDES AS ROCK INHIBITORS | Amakem NV (BE) | 2013-01-09 | — | — | EP | disclosed |
| US-20120322801-A1 | HETEROCYCLIC AMIDES AS ROCK INHIBITORS | AMAKEM NV (BE) | 2012-12-20 | — | — | US | disclosed |
| WO-2012156467-A1 | NOVEL PKC INHIBITORS | AMAKEM NV (BE) | 2012-11-22 | — | — | WO | disclosed |
| WO-2012146724-A2 | NOVEL ROCK INHIBITORS | AMAKEM NV (BE) | 2012-11-01 | — | — | WO | disclosed |
| WO-2011107608-A1 | HETEROCYCLIC AMIDES AS ROCK INHIBITORS | AMAKEM NV (BE) | 2011-09-09 | — | — | WO | disclosed |